Q-omics provides the consensus-scored THAP4 profile across patient tissues and cancer cell-line models. THAP4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, THAP4 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, THAP4 RNA expression shows 18,092 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where THAP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THAP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THAP4 survival associations across molecular data types. THAP4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THAP4 RNA expression–survival associations across cancer types. High THAP4 expression shows unfavorable associations in ACC, LIHC, LGG and UCS, but favorable associations in KIRC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for THAP4 RNA expression.
This table summarizes THAP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THAP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THAP4 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in LIHC, HNSC and LUSC. The KICH box plot shows higher THAP4 RNA expression in normal versus tumor tissue (log2 FC = −1.086, t-test p < 0.001).
This table shows molecular features associated with THAP4 in patient tissues and cancer cell lines. In patient samples, THAP4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, THAP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
